JP2012509263A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509263A5
JP2012509263A5 JP2011536395A JP2011536395A JP2012509263A5 JP 2012509263 A5 JP2012509263 A5 JP 2012509263A5 JP 2011536395 A JP2011536395 A JP 2011536395A JP 2011536395 A JP2011536395 A JP 2011536395A JP 2012509263 A5 JP2012509263 A5 JP 2012509263A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
trifluoromethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011536395A
Other languages
English (en)
Japanese (ja)
Other versions
JP5518887B2 (ja
JP2012509263A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/063370 external-priority patent/WO2010056588A1/en
Publication of JP2012509263A publication Critical patent/JP2012509263A/ja
Publication of JP2012509263A5 publication Critical patent/JP2012509263A5/ja
Application granted granted Critical
Publication of JP5518887B2 publication Critical patent/JP5518887B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011536395A 2008-11-17 2009-11-05 四置換ピリダジンヘッジホッグ経路アンタゴニスト Expired - Fee Related JP5518887B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11533208P 2008-11-17 2008-11-17
US61/115,332 2008-11-17
PCT/US2009/063370 WO2010056588A1 (en) 2008-11-17 2009-11-05 Tetrasubstituted pyridazine hedgehog pathway antagonists

Publications (3)

Publication Number Publication Date
JP2012509263A JP2012509263A (ja) 2012-04-19
JP2012509263A5 true JP2012509263A5 (OSRAM) 2012-12-13
JP5518887B2 JP5518887B2 (ja) 2014-06-11

Family

ID=41722877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536395A Expired - Fee Related JP5518887B2 (ja) 2008-11-17 2009-11-05 四置換ピリダジンヘッジホッグ経路アンタゴニスト

Country Status (18)

Country Link
US (1) US8507490B2 (OSRAM)
EP (1) EP2358698B1 (OSRAM)
JP (1) JP5518887B2 (OSRAM)
KR (1) KR101342184B1 (OSRAM)
CN (1) CN102216285B (OSRAM)
AU (1) AU2009314349B2 (OSRAM)
BR (1) BRPI0921782A2 (OSRAM)
CA (1) CA2743483C (OSRAM)
CY (1) CY1113377T1 (OSRAM)
DK (1) DK2358698T3 (OSRAM)
EA (1) EA017386B1 (OSRAM)
ES (1) ES2392759T3 (OSRAM)
HR (1) HRP20120762T1 (OSRAM)
MX (1) MX2011005177A (OSRAM)
PL (1) PL2358698T3 (OSRAM)
PT (1) PT2358698E (OSRAM)
SI (1) SI2358698T1 (OSRAM)
WO (1) WO2010056588A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0714872A2 (pt) * 2006-07-17 2013-03-19 Syngenta Participations Ag derivados de piridazina
NZ588001A (en) 2008-04-29 2012-06-29 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
AU2009320251C1 (en) 2008-11-03 2013-08-15 Eli Lilly And Company Disubstituted phthalazine Hedgehog pathway antagonists
US8445493B2 (en) 2008-11-17 2013-05-21 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105130980B (zh) * 2015-09-09 2018-05-22 沈阳药科大学 N-3-苯并咪唑噻唑胺类衍生物及其制备方法与应用
CN107163028B (zh) * 2017-05-24 2019-07-12 东南大学 一种苯甲酰胺类Hedgehog抑制剂及其制备方法和应用
CN110208424A (zh) * 2019-06-28 2019-09-06 江苏恒生检测有限公司 一种农药氟啶虫酰胺中含有杂质的分析方法
WO2021071981A1 (en) * 2019-10-08 2021-04-15 Skyhawk Therapeutics, Inc. Compounds for modulating splicing
KR20230107568A (ko) 2020-10-13 2023-07-17 엔데버 바이오메디신스, 인크. 섬유증 치료 방법
WO2023034836A1 (en) * 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
CN1104430C (zh) 1996-01-15 2003-04-02 詹森药业有限公司 抑制血管生成的哒嗪胺
CA2326654C (en) 1998-04-09 2010-11-09 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
WO2000074706A1 (en) 1999-06-08 2000-12-14 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
ATE404200T1 (de) 2002-04-22 2008-08-15 Univ Johns Hopkins Med Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
CA2564996A1 (en) 2004-05-08 2006-01-12 Taeyoung Yoon 3-aryl-5,6-disubstituted pyridazines
EP1789390B1 (en) 2004-09-02 2011-11-09 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
NZ579402A (en) 2007-03-15 2012-03-30 Novartis Ag Organic compounds for diagnosis and treatment of pathologies relating to the Hedgehog pathway
AU2008269128B2 (en) 2007-06-25 2012-08-02 Amgen Inc. Phthalazine compounds, compositions and methods of use
ES2392157T3 (es) 2007-09-07 2012-12-05 Amgen Inc. Piridazinas anilladas para el tratamiento de tumores dirigidos por señalización Hedgehog inapropiada
NZ588001A (en) 2008-04-29 2012-06-29 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
AU2009320251C1 (en) 2008-11-03 2013-08-15 Eli Lilly And Company Disubstituted phthalazine Hedgehog pathway antagonists
US8445493B2 (en) 2008-11-17 2013-05-21 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Similar Documents

Publication Publication Date Title
JP2012509263A5 (OSRAM)
JP2012530705A5 (OSRAM)
JP2012507535A5 (OSRAM)
JP2014139226A5 (OSRAM)
JP2009526072A5 (OSRAM)
HRP20120762T1 (hr) Tetrasupstituirani piridazini kao inhibitori hedgehog puta
JP2013537203A5 (OSRAM)
NZ547615A (en) Quinoline derivatives and use thereof as mycobacterial inhibitors
JP2011527666A5 (OSRAM)
JP2011529054A5 (OSRAM)
JP2015524472A5 (OSRAM)
JP2014507464A5 (OSRAM)
JP2018502877A5 (OSRAM)
JP2012533546A5 (OSRAM)
JP2018507877A5 (OSRAM)
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
NZ703941A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2013543896A5 (OSRAM)
JP2011519854A5 (OSRAM)
CA2579915A1 (en) Indole derivatives and their use as inhibitors of p53-mdm2 interaction
WO2009080836A3 (en) Macrocyclic indoles as hepatitis c virus inhibitors
JP2016506962A5 (OSRAM)
JP2010527365A5 (OSRAM)
JP2019518770A5 (OSRAM)
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate